NAFLD and New-Onset Heart Failure: What is the Link?
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Patient Awareness – Education
Discover key patient awareness resources, encompassing the latest research and information on Non-Alcoholic Steatohepatitis (NASH) and the role of PPAR agonists.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?
Adipose tissue insulin resistance and fibrosis stage in NASH
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
A Transformative Shift in Liver Disease Terminology: NAFLD Becomes MASLD
The multinational liver societies introduce a non-stigmatizing and affirming nomenclature for "Fatty" liver diseases, striving for a global consensus to advance research, funding, and patient care.
Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
MASLD: A New Fatty Liver Disease Nomenclature?
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Measuring NAFLD Models of Care: A New Strategic Framework?
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
NAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.